To appraise the clinical and cost-effectiveness of atezolizumab in combination with gemcitabine and carboplatin within its marketing authorisation for urothelial carcinoma
Following on from information provided to NICE by the company in March 2021, the appraisal of Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1206
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Roche (Atezolizumab with gemcitabine and carboplatin)
- Others
- Department of Health and Social Care
- NHS England
- NHS Greater Preston CCG
- NHS Hartlepool and Stockton-on-Tees CCG
- Welsh Government
- Patient carer groups
- Action Bladder Cancer UK
- Black Health Agency for Equality
- Bladder and Bowel Community
- Bladder and Bowel UK
- Cancer 52
- Cancer Black Care
- Cancer Equality
- Fight Bladder Cancer
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Pelican Cancer Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- British Association of Urological Nurses
- British Association of Urological Surgeons
- British Geriatrics Society
- British Gynaecological Cancer Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Society of Urogenital Radiology
- British Society of Urogynaecology
- British Uro-Oncology Group
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Urology Foundation
- Associated guideline groups
- National Guideline Centre
- Associated public health groups
- Public Health England
- Public Health Wales
- Comparator companies
- Accord Healthcare (carboplatin, cisplatin, doxorubicin, gemcitabine, methotrexate)
- Allergan (gemcitabine)
- Amgen (pegfilgrastim)
- Chugai Pharma (lenograstim)
- Concordia International (methotrexate)
- Hospira UK (carboplatin, cisplatin, gemcitabine, methotrexate, vinblastine)
- Janssen-Cilag (doxorubicin)
- Lilly UK (gemcitabine)
- Medac GmbH (doxorubicin, gemcitabine)
- Merck Sharp & Dohme (pembrolizumab)
- Nordic Pharma (methotrexate)
- Orion Pharma (methotrexate)
- Pfizer (doxorubicin, methotrexate, vinblastine)
- Rosemont Pharmaceuticals (methotrexate)
- Sandoz (cisplatin, methotrexate)
- Seacross Pharmaceuticals (doxorubicin)
- Sun Pharma (carboplatin, gemcitabine)
- Teva UK (doxorubicin, lipegfilgrastim, methotrexate)
- Therakind (methotrexate)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Cochrane Urology
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Leeds Institute of Cancer & Pathology
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Following on from information provided to NICE by the company in March 2021, the appraisal of Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2021, the appraisal of Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 November 2020 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 28 August 2020 | Invitation to participate |
| 18 May 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of atezolizumab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic urothelial bladder cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised and we now anticipate that the appraisal will begin during late August 2020 when we will write to you about how you can get involved. |
| 21 November 2019 - 28 November 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 09 February 2018 | In progress. Topic referred 21 April 2017 |
For further information on our processes and methods, please see our CHTE processes and methods manual